Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synergy CHCSNYR +34.66% 3-Year RORE % is 346.46 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 114 Medical Distribution companies, Synergy CHC ranks better than 97.37% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Synergy CHC's 3-Year RORE % for the quarter that ended in Mar. 2026 was 346.46%.
The industry rank for Synergy CHC's 3-Year RORE % or its related term are showing as below:
SNYR's 3-Year RORE % is ranked better than 97.37% of 114
companies
in the Medical Distribution industry
Industry Median: 7.665
vs SNYR: 346.46
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Synergy CHC 3-Year RORE % Related Terms
Synergy CHC 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Synergy CHC's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Synergy CHC's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synergy CHC 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Synergy CHC's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Synergy CHC's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Synergy CHC (SNYR) has a 3-Year RORE % of 346.46 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Synergy CHC and its competitors. According to the industry distribution chart, Synergy CHC ranks #3 out of 114 companies in the Medical Distribution industry, placing it in the top 2.6%.
Is Synergy CHC's 3-Year RORE % too high?
Synergy CHC's current 3-Year RORE % is 346.46. The Medical Distribution industry median 3-Year RORE % is 7.67. Synergy CHC's value of 346.46 is 4420% above this industry median. Based on the distribution chart, Synergy CHC ranks #3 out of 114 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers.
How does Synergy CHC's 3-Year RORE % compare to MEDS and MCK?
According to the Medical Distribution industry distribution chart, Synergy CHC ranks #3 out of 114 companies for 3-Year RORE %. This places Synergy CHC in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 7.67. Synergy CHC's value of 346.46 is 4420% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 7.67, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synergy CHC's current 3-Year RORE % of 346.46 is 4420% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Synergy CHC and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 7.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synergy CHC's current 3-Year RORE % is 346.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synergy CHC stock overvalued right now?
Based on GuruFocus' analysis, Synergy CHC (SNYR) is currently considered Possible Value Trap. The stock's GF Value™ is $1.08, compared to a current price of $0.11 — trading 90% below its estimated fair value. The current 3-Year RORE % is 346.46 and 4420% above the Medical Distribution industry median of 7.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Synergy CHC (SNYR), the current 3-Year RORE % is 346.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer-branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen, amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNYR has been successfully added to your 
